ClaudioGarciaBrunsteinMDPhD(He/Him)

Hematology • Cleveland, OH

Hematologic Oncology

Cleveland Clinic Foundation, Cleveland, OH

Join to view full profile

Dr. Brunstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brunstein's full profile

Already have an account?

Office
10201 Carnegie Ave
CA-60
Cleveland, OH 44195

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1998 - 2002
Federal University of Rio Grande do Sul School of MedicineClass of 1990

Certifications & Licensure

OH State Medical License 2022 - 2026
MN State Medical License 2002 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer Start of enrollment: 2001 Apr 01
Completed
Not Applicable
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Start of enrollment: 2005 Jun 01
Completed
Phase 2
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Start of enrollment: 2005 Jul 28
Completed
Phase 2
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 1, Phase 2
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases Start of enrollment: 2007 May 01
Terminated
Phase 1
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Start of enrollment: 2007 Jul 23
Completed
Phase 1
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 1, Phase 2
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Start of enrollment: 2014 Jan 01
Withdrawn
Phase 1, Phase 2
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units Start of enrollment: 2011 Oct 20
Recruiting
Not Applicable
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Start of enrollment: 2016 Dec 01
Recruiting
Not Applicable
Treg Cells for AGVHD in Non-myeloablative UCB Transplant Start of enrollment: 2016 Jun 01
Withdrawn
Phase 2
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies Start of enrollment: 2014 Sep 02
Recruiting
Not Applicable
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Start of enrollment: 2017 May 15
Active, not recruiting
Phase 2
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Start of enrollment: 2017 Feb 16
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

72 citations
Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD
Nelli Bejanyan, Claudio G. Brunstein, Qing Cao, Aleksandr Lazaryan, Xianghua Luo
Blood Advances. 2018-04-24
58 citations
Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival
Pablo A. Ramirez, Claudio G. Brunstein, Bradley S. Miller, Todd E. DeFor, Daniel J. Weisdorf
Bone Marrow Transplantation. 2011-07-01
391 citations
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
Shernan G. Holtan, Todd E. DeFor, Aleksandr Lazaryan, Nelli Bejanyan, Mukta Arora
Blood. 2015-02-19

Journal Articles

Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics
Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica

Abstracts/Posters

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Uni...
Claudio G. Brunstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
Claudio G. Brunstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
Claudio G. Brunstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Romiplostim Improves Platelet Recovery after UCB Transplant
Claudio G. Brunstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

University of Minnesota Opens First-Ever U.S. Clinical Trial of Engineered iPSC-Derived Cell Therapy for Blood CancerOctober 23rd, 2019
First-Ever US Clinical Trial of Engineered iPSC-Derived Cell Therapy for Blood CancerOctober 21st, 2019
Half-Matched Transplants Widen Pool of Donors for Leukemia and LymphomaJuly 8th, 2011